Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Bosentan products are in shortage in Canada (2 of 12 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jun 30, 2027.
A medication used to treat pulmonary arterial hypertension.
Products affected
2 / 12
In shortage since
Nov 18, 2024
Est. full return
Jun 30, 2027
Reports on file
18
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
NAT-BOSENTAN
125MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02467992 · since Nov 18, 2024, est. end Jun 30, 2027 · Long Term Back Order
Active shortage
NAT-BOSENTAN
62.5MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02467984 · since Nov 18, 2024, est. end Jun 30, 2027 · Long Term Back Order
Resolved
TARO-BOSENTAN
125MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483149 · ended Aug 8, 2025 · Disruption of the manufacture of the drug.
Resolved
TARO-BOSENTAN
62.5MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483130 · ended Aug 8, 2025 · Disruption of the manufacture of the drug.
Avoided
SANDOZ BOSENTAN
125MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02386283 · ended Jan 30, 2021 · Disruption of the manufacture of the drug.
Resolved
TARO-BOSENTAN
125MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483149 · ended Jun 30, 2023 · Disruption of the manufacture of the drug.
Resolved
TARO-BOSENTAN
62.5MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483130 · ended Jun 30, 2023 · Disruption of the manufacture of the drug.
Discontinued
PMS-BOSENTAN
125MG · TABLET · PHARMASCIENCE INC
DIN 02383020
Discontinued
PMS-BOSENTAN
62.5MG · TABLET · PHARMASCIENCE INC
DIN 02383012
Discontinued
APO-BOSENTAN
125.0MG · TABLET · APOTEX INC
DIN 02399210
Discontinued
APO-BOSENTAN
62.5MG · TABLET · APOTEX INC
DIN 02399202
Discontinued
APO-BOSENTAN
125.0MG · TABLET · APOTEX INC
DIN 02399210
Showing 12 of 18 reports. All reports are on file with Health Canada.
What's happening
Bosentan is currently affected by 2 active shortage reports filed with Health Canada by NATCO PHARMA (CANADA) INC.
The reported cause is: long term back order. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Bosentan is classified under “OTHER ANTIHYPERTENSIVES” (ATC C02KX).
Recent changes
No changes recorded yet.
Common questions
What is Bosentan used for?
A medication used to treat pulmonary arterial hypertension.
When will Bosentan be back in stock in Canada?
The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Bosentan in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.